Piper Sandler Cuts Axon Enterprise (NASDAQ:AXON) Price Target to $690.00

Axon Enterprise (NASDAQ:AXON) had its price target cut by Piper Sandler from $753.00 to $690.00 in a research report sent to investors on Wednesday, MarketBeat reports. They currently have an overweight rating on the biotechnology company’s stock.

Other analysts also recently issued reports about the stock. Morgan Stanley cut their target price on shares of Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 17th. UBS Group dropped their price target on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Northcoast Research raised Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective for the company in a research note on Tuesday, January 6th. Barclays lowered their target price on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Finally, Royal Bank Of Canada began coverage on shares of Axon Enterprise in a research report on Monday, November 17th. They issued an “outperform” rating and a $860.00 price target for the company. Sixteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $762.93.

Axon Enterprise Price Performance

NASDAQ AXON opened at $542.40 on Wednesday. The company has a current ratio of 2.53, a quick ratio of 2.89 and a debt-to-equity ratio of 0.53. Axon Enterprise has a 1 year low of $396.41 and a 1 year high of $885.91. The company has a market cap of $43.61 billion, a PE ratio of 356.84, a PEG ratio of 16.57 and a beta of 1.48. The stock’s 50-day moving average price is $537.92 and its two-hundred day moving average price is $625.54.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping the consensus estimate of $1.60 by $0.55. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. During the same period last year, the company posted $2.08 earnings per share. The business’s revenue for the quarter was up 38.5% on a year-over-year basis. On average, analysts predict that Axon Enterprise will post 5.8 EPS for the current year.

Insider Activity

In other Axon Enterprise news, CFO Brittany Bagley sold 2,000 shares of Axon Enterprise stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $580.00, for a total value of $1,160,000.00. Following the completion of the sale, the chief financial officer directly owned 103,501 shares in the company, valued at $60,030,580. The trade was a 1.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $551.92, for a total transaction of $5,519,200.00. Following the transaction, the chief executive officer owned 3,110,997 shares in the company, valued at approximately $1,717,021,464.24. This trade represents a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 58,040 shares of company stock valued at $32,251,738. 4.40% of the stock is currently owned by company insiders.

Institutional Trading of Axon Enterprise

Several large investors have recently made changes to their positions in AXON. Creative Financial Designs Inc. ADV acquired a new stake in Axon Enterprise in the 4th quarter worth approximately $28,000. Stone House Investment Management LLC acquired a new stake in shares of Axon Enterprise in the third quarter worth $29,000. New Millennium Group LLC bought a new stake in shares of Axon Enterprise during the 3rd quarter worth $29,000. Sound Income Strategies LLC grew its stake in Axon Enterprise by 550.0% in the 4th quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 44 shares during the last quarter. Finally, Camelot Portfolios LLC acquired a new position in Axon Enterprise during the 4th quarter worth $30,000. Institutional investors own 79.08% of the company’s stock.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.